125 related articles for article (PubMed ID: 18434224)
1. A comparison of toxicity of two dosing schemes for doxorubicin in the cat.
Reiman RA; Mauldin GE; Neal Mauldin G
J Feline Med Surg; 2008 Aug; 10(4):324-31. PubMed ID: 18434224
[TBL] [Abstract][Full Text] [Related]
2. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.
Ogilvie GK; Moore AS; Obradovich JE; Elmslie RE; Vail DM; Straw RC; Salmon MD; Klein MK; Atwater SW; Ciekot PE
J Am Vet Med Assoc; 1993 Jun; 202(11):1839-44. PubMed ID: 8320152
[TBL] [Abstract][Full Text] [Related]
3. Rescue therapy with doxorubicin-based chemotherapy for relapsing or refractory feline lymphoma: a retrospective study of 23 cases.
Oberthaler KT; Mauldin E; McManus PM; Shofer FS; Sorenmo KU
J Feline Med Surg; 2009 Apr; 11(4):259-65. PubMed ID: 18974017
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of, and toxicoses associated with, oral idarubicin administration in cats with neoplasia.
Moore AS; Ruslander D; Cotter SM; Rand WM; L'Heureux DA
J Am Vet Med Assoc; 1995 May; 206(10):1550-4. PubMed ID: 7775231
[TBL] [Abstract][Full Text] [Related]
5. Systemic toxicity associated with doxorubicin administration in cats.
O'Keefe DA; Sisson DD; Gelberg HB; Schaeffer DJ; Krawiec DR
J Vet Intern Med; 1993; 7(5):309-17. PubMed ID: 8263850
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of radiotherapy alone or in combination with doxorubicin chemotherapy for the treatment of cats with incompletely excised soft tissue sarcomas: 71 cases (1989-1999).
Hahn KA; Endicott MM; King GK; Harris-King FD
J Am Vet Med Assoc; 2007 Sep; 231(5):742-5. PubMed ID: 17764436
[TBL] [Abstract][Full Text] [Related]
7. Ketoconazole for treatment of dermatophytosis in cats.
Medleau L; Chalmers SA
J Am Vet Med Assoc; 1992 Jan; 200(1):77-8. PubMed ID: 1537696
[TBL] [Abstract][Full Text] [Related]
8. Surgery alone versus surgery and doxorubicin for the treatment of feline injection-site sarcomas: a report on 69 cases.
Martano M; Morello E; Ughetto M; Iussich S; Petterino C; Cascio P; Buracco P
Vet J; 2005 Jul; 170(1):84-90. PubMed ID: 15993791
[TBL] [Abstract][Full Text] [Related]
9. Comparison of body surface area-based and weight-based dosage protocols for doxorubicin administration in dogs.
Arrington KA; Legendre AM; Tabeling GS; Frazier DL
Am J Vet Res; 1994 Nov; 55(11):1587-92. PubMed ID: 7879983
[TBL] [Abstract][Full Text] [Related]
10. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors.
Ogilvie GK; Richardson RC; Curtis CR; Withrow SJ; Reynolds HA; Norris AM; Henderson RA; Klausner JS; Fowler JD; McCaw D
J Am Vet Med Assoc; 1989 Dec; 195(11):1584-7. PubMed ID: 2599942
[TBL] [Abstract][Full Text] [Related]
11. Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment.
Gagnon J; Dervisis NG; Kitchell BE
J Feline Med Surg; 2012 Aug; 14(8):560-5. PubMed ID: 22496148
[TBL] [Abstract][Full Text] [Related]
12. Treatment of ethylene glycol toxicosis in cats.
Penumarthy L; Oehme FW
Am J Vet Res; 1975 Feb; 36(2):209-12. PubMed ID: 1111386
[TBL] [Abstract][Full Text] [Related]
13. Clinical investigation of doxorubicin, daunomycin, and 6-thioguanine in normal cats.
Henness AM; Theilen GH; Lewis JP
Am J Vet Res; 1977 Apr; 38(4):521-4. PubMed ID: 851285
[TBL] [Abstract][Full Text] [Related]
14. Proteasomes are not a target for doxorubicin in feline injection-site sarcoma.
Cerruti F; Martano M; Morello E; Buracco P; Cascio P
J Comp Pathol; 2010; 143(2-3):164-72. PubMed ID: 20427050
[TBL] [Abstract][Full Text] [Related]
15. Effect of a 1-hour IV infusion of doxorubicin on the development of cardiotoxicity in dogs as evaluated by electrocardiography and echocardiography.
Gillings S; Johnson J; Fulmer A; Hauck M
Vet Ther; 2009; 10(1-2):46-58. PubMed ID: 19742448
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
17. Effect of infusion regime on doxorubicin pharmacokinetics in the cat.
Hahn KA; Frazier DL; Cox SK; Legendre AM
J Am Anim Hosp Assoc; 1997; 33(5):427-33. PubMed ID: 9278119
[TBL] [Abstract][Full Text] [Related]
18. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of doxorubicin thermosensitive liposomes (40 degrees C) and local hyperthermia on rat rhabdomyosarcoma.
Morita K; Zywietz F; Kakinuma K; Tanaka R; Katoh M
Oncol Rep; 2008 Aug; 20(2):365-72. PubMed ID: 18636199
[TBL] [Abstract][Full Text] [Related]
20. Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen.
Fan TM; Kitchell BE; Dhaliwal RS; Jones PD; Hintermeister JG; Paria BC
J Am Anim Hosp Assoc; 2002; 38(4):357-63. PubMed ID: 12118689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
